Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress(TM)
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical data on ARC-520, ARC-521, and ARC-AAT, the company's prior generation investigational medicines that were being studied for the treatment of chronic hepatitis B infection and liver disease associated with alpha-1 antitrypsin deficiency, at The International Liver Congress™ 2017 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL) being held in Amsterdam, the Netherlands from April 19-23, 2017. Oral Presentations: Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen
Presentation Reference: PS-045
Session: Parallel session: Hepatitis B and D: Emerging treatment options
Date and Time: April 20, 2017 at 5:30 PM CET
Authors: Man-Fung Yuen, et al.
Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients
Presentation Reference: LBO-06
Session: Late Breaker session
Date and Time: April 22, 2017 at 5:15 PM CET
Authors: Alice Turner, et al.
Poster Presentation: A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer population
Presentation Reference: THU-176
Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
Authors: Edward Gane, et al.
Additional details including presentation abstracts can be found on the ILC website at https://ilc-congress.eu/. A copy of presentation materials can be accessed by visiting the Events section of the Arrowhead website after the presentations conclude.
Arrowhead announced on November 29, 2016 that it had discontinued development of ARC-520, ARC-521, and ARC-AAT. The company continues to develop ARO-HBV and ARO-AAT, which are follow on investigational RNAi therapeutics against chronic hepatitis B infection and alpha-1 liver disease that utilize the company's new proprietary subcutaneous delivery system.
The International Liver Congress is a trademark of the European Association for the Study of the Liver. 作者: StephenW 时间: 2017-4-5 20:43
Arrowhead Pharmaceuticals Announces Presentations at The International Liver
Congress™
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will
present clinical data on ARC-520, ARC-521, and ARC-AAT, the company's prior generation investigational medicines that
were being studied for the treatment of chronic hepatitis B infection and liver disease associated with alpha-1 antitrypsin
deficiency, at The International Liver Congress™ 2017 (ILC), the annual meeting of the European Association for the Study
of the Liver (EASL) being held in Amsterdam, the Netherlands from April 19-23, 2017.
Oral Presentations:
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative
patients with chronic HBV results in significant reductions of HBs antigen
Presentation Reference: PS-045
Session: Parallel session: Hepatitis B and D: Emerging treatment options
Date and Time: April 20, 2017 at 5:30 PM CET
Authors: Man-Fung Yuen, et al.
Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ
patients
Presentation Reference: LBO-06
Session: Late Breaker session
Date and Time: April 22, 2017 at 5:15 PM CET
Authors: Alice Turner, et al.
Poster Presentation:
A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug
ARC-521 in a healthy volunteer population
Presentation Reference: THU-176
Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
Authors: Edward Gane, et al.
Additional details including presentation abstracts can be found on the ILC website at https://ilc-congress.eu/. A copy of
presentation materials can be accessed by visiting the Events section of the Arrowhead website after the presentations
conclude.
Arrowhead announced on November 29, 2016 that it had discontinued development of ARC-520, ARC-521, and ARC-AAT.
The company continues to develop ARO-HBV and ARO-AAT, which are follow on investigational RNAi therapeutics against
chronic hepatitis B infection and alpha-1 liver disease that utilize the company's new proprietary subcutaneous delivery
system.
The International Liver Congress is a trademark of the European Association for the Study of the Liver.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA
interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a
specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to
the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of
the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking
statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the
duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We assume no obligation to update or revise forwardlooking
statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170405005323/en/作者: 齐欢畅2 时间: 2017-4-5 21:56
ARO-HBV
ARO-HBV is being developed to be a potentially curative therapy for patients with chronic hepatitis B infection. ARO-HBV silences all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. The company believes this will allow the body’s natural immune defenses to clear the virus and lead to a functional cure.
Disease
Chronic hepatitis B infection is the most common serious liver infection. Current drugs suppress viral replication but rarely lead to a cure and therefore must be taken indefinitely. Developing curative therapy is a priority.
There are 16 million people with chronic hepatitis B in the U.S. and Western Europe and 400 million people worldwide. In the immune tolerant phase of chronic infection, which can last for many years, the infected person typically produces very high levels of viral DNA and viral antigens. However, the infection is not cytotoxic and the carrier may have no symptoms of illness. Over time, the ongoing production of viral antigens causes inflammation and necrosis, leading to cirrhosis and liver cancer (HCC). Hepatitis B is responsible for 80% of primary liver cancers.
The current standard of care for treatment of chronic HBV infection is a daily oral dose of nucleotide/nucleoside analogs (NUCs) or a regimen of interferon injections for approximately one year. NUCs are generally well tolerated, but patients may need lifetime treatment because viral replication often rebounds upon cessation of treatment. Interferon therapeutics can result in a functional cure in around 10% of some patient types, but treatment is often associated with significant side effects, including severe flu-like symptoms, bone marrow suppression, and autoimmune disorders.